PAVmed

Nasdaq: PAVM

Q1 2026 Business Update

May 15, 2026

LISHAN AKLOG, MD
Chairman & CEO

DENNIS MCGRATH
President & CFO



Disclaimer

- This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the “Companies”) that involve risks and uncertainties.
- Actual results and events may differ significantly from results and events discussed in forward-looking statements.
- Factors that might cause or contribute to such differences include, but are not limited to, those discussed in “Risk Factors” in the Companies’ Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
- The Companies undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made.
- This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
- The Companies may not yet have received clearance from the FDA or any other regulatory agency for some of the products described in this presentation.

PAVmed

Nasdaq: PAVM

Lishan Aklog, M.D.
Chairman & CEO



PAVmed Corporate Structure

PAVmed

Nasdaq: PAVM

DIAGNOSTICS

Lucid diagnostics

Nasdaq: LUCD

Early Detection of Esophageal Precancer

DIGITAL HEALTH

Veris Health

Privately Held

Digital Cancer Care Platform & Smart Vascular Access Port

Medical Device Portfolio

Privately Held

Incubator for MedTech Technologies, including PortIO and EsoCure

Recent Highlights

Veris Health

- **Commercial phase of** OSU strategic engagement well underway
- Clinical rollout to expand to **additional departments**
- **EHR integration** working well
- Implantable physiological monitor development progressing toward planned end of 2026 **FDA 510(k) submission**
- Partnership with new **contract development and manufacturing** firm going well
- **Expanded strategic vision** for Company's next phase being finalized
  - **Commercial expansion and transformation beyond remote patient monitoring (RPM)**

PAVmed

Nasdaq: PAVM

Q1 2026
Financial Update



Balance Sheet

($ in thousands)	1Q26	4Q25	Change
Assets			
Cash	$6,460	$1,538	$4,922
Equity Method Investments (Lucid)	$35,998	$34,120	$1,878
All other Assets	$2,961	$3,154	$(193)
Liabilities			
Accounts Payable	$983	$678	$305
Senior Secured Convertible Notes	$14,900	$11,100	$3,800
Other Liabilities	$4,548	$4,734	$(186)
Series C Convertible Preferred	$-	$21,013	$(21,013)
Shares Outstanding	6.27M	0.93M	5.34M

P&L

($ in thousands)	1Q26	1Q25	Change
Revenue + Management Fee Income	$3,178	$3,158	$20
Operating Expenses	$8,057	$5,454	$2,603
Net Income (Loss)	$(1,064)	$18,623	$(19,687)
EBITDA	$(307)	$19,007	$(19,314)
Stock-Based Compensation	$182	$930	$(748)
Non-GAAP Adjusted Loss	$(1,851)	$(910)	$(941)
Non-GAAP Adjusted Loss per Share	$(1.17)	$(1.97)	$0.80

To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certainexpenses, gains, and losses that may not be indicative of our core operating results and business outlook and believes non-GAAP financial measures enhance the comparability of results against prior periods. A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this presentation and the corresponding press release for the three months ended March 31, 2026 are reflected above.

Non-GAAP Operating Expense



To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certainexpenses, gains, and losses that may not be indicative of our core operating results and business outlook and believes non-GAAP financial measures enhance the comparability of results against prior periods. A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this presentation and the corresponding press release for the three months ended March 31, 2026 are reflected above.

PAVmed

Nasdaq: PAVM

Q&A



PAVmed

Nasdaq: PAVM

Closing Remarks

